Basket cover image
17 handpicked stocks

Best In Class

Meet the true champions of the market. These carefully selected stocks represent the single most influential company in each economic sector, chosen by expert analysts for their market dominance and enduring competitive advantages.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+7

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at जून 17

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

MSFT

Microsoft Corporation

MSFT

Current price

$509.77

Leads the technology sector with its dominant enterprise software, cloud computing services, and extensive market penetration.

WMT

Walmart Inc.

WMT

Current price

$101.29

The undisputed leader in the retail sector, defined by its extensive global footprint and mastery of supply chain logistics.

JNJ

Johnson & Johnson

JNJ

Current price

$177.80

A diversified leader in healthcare, commanding major market share in pharmaceuticals, medical devices, and consumer health products.

About This Group of Stocks

1

Our Expert Thinking

We've identified the absolute titans across every major economic sector. These aren't just big companies – they're the undisputed leaders who set industry standards through their scale, brand power, and operational excellence, creating formidable competitive moats.

2

What You Need to Know

Each company here ranks #1 in its respective industry based on market capitalization and financial health. This collection works as a core, diversified holding that gives you broad economic exposure through proven market winners with demonstrated staying power.

3

Why These Stocks

These industry champions were handpicked for their market leadership positions and financial strength. Their massive scale gives them unique advantages, including the ability to fund and integrate next-generation technologies like AI, potentially widening their lead.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+14.88%

Group Performance Snapshot

14.88%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 14.88% over the next year.

15 of 16

Stocks Rated Buy by Analysts

15 of 16 assets in this group are rated Buy by professional analysts.

2.8%

Group Growth

This group averaged a 2.8% return last month.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

👑

Industry Royalty

These market leaders sit at the top of their respective industries, giving you access to the most influential companies across the entire economy in a single collection.

🛡️

Built-In Staying Power

Market leaders typically weather economic storms better than smaller competitors. Their established dominance and financial strength can provide stability when markets get choppy.

🔮

First Access to Innovation

These giants have the resources to invest heavily in AI and other emerging technologies, potentially widening their competitive advantages in ways smaller players simply can't match.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.